Jump to navigation
OHE Consulting produces a report on Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS.
This year marks the 70th birthday of the NHS. Our latest Consulting Report describes the most important new medicines as identified by experts.
OHE Consulting produces a report critiquing a paper by Hill et al. (2018) on estimated costs of production for the WHO Essential Medicines List.
OHE Consulting has produced a report summarising the literature on indication-based pricing and how it has been applied in the U.S. and 5 European countries.
A new OHE report discusses NICE’s introduction of a cost-effectiveness threshold to appraise ultra-orphan drugs.
OHE Consulting publishes a report on the barriers to the uptake of minimal access surgery in the NHS and private sector.
A recent paper examines EQ-5D-5L outcomes in patients with overactive bladder and compares them to results on the OAB-5D, a condition-specific measure.
This report explores the consequences of the exit of the United Kingdom (UK) from the European Union (EU) on public health in the UK and in the EU.
OHE’s Deputy Director Paula Lorgelly is standing as a candidate for the International Health Economics Association Board of Directors
For Open Access Week 2017, the Office of Health Economics highlights its research publication archive dating back to 1962
OHE Lunchtime Seminar: Price Regulation of Generics and Drug Shortages
OHE at ISPOR Europe 2018
OHE at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare October, 2018